Viking Therapeutics – Common Stock Purchase Warrant Viking Therapeutics, Inc. (June 19th, 2017)
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, _____________ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after six (6) months after the date hereof (the "Initial Exercise Date") and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the "Termination Date"; provided, however that if such date is not a Trading Day, the Termination Date shall be the immediately following Trading Day) but not thereafter, to subscribe for and purchase from Viking Therapeutics, Inc., a Delaware corporation (the "Company"), up to ______ shares of Common Stock, par value $0.00001 per share (the "Common Stock") (as subject to adjustment hereunder, the "Warrant Shares"). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Viking Therapeutics – Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement With Aspire Capital (August 25th, 2016)
Under the terms of the agreement, Aspire Capital has made an initial purchase of $500,000 of Viking common stock at $1.50 per share, which represents a 15% premium over the August 24 closing price of $1.31. In addition, after the Securities and Exchange Commission (SEC) declares the registration statement related to the transaction effective, Aspire Capital has committed to purchase up to an additional $12.0 million in shares of common stock over the next 30 months at prices based on the market price at the time of each sale. No warrants, derivatives, or other share classes are associated with this agreement. Proceeds from the stock purchase agreement will be used for general corporate purposes, including advancing the company's drug development pipeline.
Viking Therapeutics – Common Stock Purchase Agreement (August 25th, 2016)
COMMON STOCK PURCHASE AGREEMENT (the "Agreement"), dated as of August 24, 2016, by and between VIKING THERAPEUTICS, INC., a Delaware corporation (the "Company"), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the "Buyer"). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
Viking Therapeutics – Second Amendment to Employment Agreement (March 15th, 2016)
This Second Amendment to Employment Agreement (this "Amendment"), effective as of March 14, 2016, is made by and between Viking Therapeutics, Inc. (the "Company") and Michael Morneau ("Executive").
Viking Therapeutics – First Amendment to Employment Agreement (March 15th, 2016)
This First Amendment to Employment Agreement (this "Amendment"), effective as of March 14, 2016, is made by and between Viking Therapeutics, Inc. (the "Company") and Brian Lian, Ph.D. ("Executive").